DGAP-News: CO.DON AG / Key word(s): Miscellaneous
06.12.2017 / 15:20
The issuer is solely responsible for the content of this announcement.
CO.DON AG – Changes in the Supervisory Board
Berlin / Teltow, 06.12.2017 – With effect from 1 December Mr. Professor Bauerfeind is appointed Chairman of the Supervisory Board of CO.DON AG. The Vice Chair will be the long-standing member of the Supervisory Board, Mr. Thommy Stählin.
Mr. Dr. Wegener has for private reasons decided to resign as Chairman but continues as a member of the Supervisory Board.
Dr. Wegener: “Reaching the age of 70 I will decrease my engagement with CO.DON AG. I am proud of the accomplishments and long journey towards commercialisation of an innovative ATMP together with CO.DON. And I would like to extend my gratitude to my colleagues in the Supervisory Board, the Executive Management and all employees for their commitment and efforts.”
Professor Bauerfeind: “On behalf of the entire Supervisory Board I would like to express my sincere thanks to Mr. Dr. Wegener for his leadership as Chairman and for his strength, foresight and determination. During his chairmanship the most recent milestone was the European Marketing Authorisation for a cartilage repair product developed by CO.DON – a tremendously important and strategic objective for the company.”
Dirk Hessel, CEO of CO.DON AG: “Dr. Wegener has accompanied CO.DON for years. In addition to his financial commitment as a major shareholder as well as his extensive experience, advice and strategic direction in decisions has been instrumental for where CO.DON is today. We acknowledge this, are grateful and pass on our best wishes. “
CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage damage in knee joints following traumatic or degenerative defects. The product being marketed is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). CO.DON’s method has been used for more than 10 years in over 150 clinics to treat more than 11,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007. In July 2017 the company received EU marketing authorization for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).
More information can be found at www.codon.de
Investor Relations and Press Contact:
06.12.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|